Repulsive Guidance Molecule (RGM) Family Proteins Exhibit Differential Binding Kinetics for Bone Morphogenetic Proteins (BMPs) by Wu, Qifang et al.
 
Repulsive Guidance Molecule (RGM) Family Proteins Exhibit
Differential Binding Kinetics for Bone Morphogenetic Proteins
(BMPs)
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Wu, Qifang, Chia Chi Sun, Herbert Y. Lin, and Jodie L. Babitt.
2012. Repulsive guidance molecule (RGM) family proteins exhibit
differential binding kinetics for bone morphogenetic proteins
(BMPs). PLoS ONE 7(9): e46307.
Published Version doi:10.1371/journal.pone.0046307
Accessed February 19, 2015 11:51:36 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10522917
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARepulsive Guidance Molecule (RGM) Family Proteins
Exhibit Differential Binding Kinetics for Bone
Morphogenetic Proteins (BMPs)
Qifang Wu, Chia Chi Sun, Herbert Y. Lin, Jodie L. Babitt*
Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard
Medical School, Boston, Massachusetts, United States of America
Abstract
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor beta superfamily that exert their
effects via type I and type II serine threonine kinase receptors and the SMAD intracellular signaling pathway to regulate
diverse biologic processes. Recently, we discovered that the repulsive guidance molecule (RGM) family, including RGMA,
RGMB, and RGMC/hemojuvelin (HJV), function as co-receptors that enhance cellular responses to BMP ligands. Here, we use
surface plasmon resonance to quantitate the binding kinetics of RGM proteins for BMP ligands. We show that among the
RGMs, HJV exhibits the highest affinity for BMP6, BMP5, and BMP7 with KD 8.1, 17, and 20 nM respectively, versus 28, 33, and
166 nM for RGMB, and 55, 83, and 63 nM for RGMA. Conversely, RGMB exhibits preferential binding to BMP4 and BMP2 with
KD 2.6 and 5.5 nM respectively, versus 4.5 and 9.4 nM for HJV, and 14 and 22 nM for RGMA, while RGMA exhibits the lowest
binding affinity for most BMPs tested. Among the BMP ligands, RGMs exhibit the highest relative affinity for BMP4 and the
lowest relative affinity for BMP7, while none of the RGMs bind to BMP9. Thus, RGMs exhibit preferential binding for distinct
subsets of BMP ligands. The preferential binding of HJV for BMP6 is consistent with the functional role of HJV and BMP6 in
regulating systemic iron homeostasis. Our data may help explain the mechanism by which BMPs exert cell-context specific
effects via a limited number of type I and type II receptors.
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Introduction
Bone morphogenetic proteins (BMPs) are a subfamily of the
transforming growth factor beta (TGF-b) superfamily of signaling
molecules that is comprised of over 40 members [1]. Although best
characterized for their roles during development due to the
frequent embryonic lethality or major organ malformation caused
by functional loss of BMP/TGF-b signaling pathway components,
there is an increasingly recognized role for BMP/TGF-b super-
family signaling during postnatal life [2].
BMP/TGF-b superfamily members exert their effects by
binding to a complex of two type I and two type II serine
threonine kinase receptors to stimulate phosphorylation of in-
tracellular SMAD proteins, which complex with common-
mediator SMAD4 and translocate to the nucleus to regulate gene
transcription [1–2]. Thus far, 7 type I receptors (4 for the BMP
subfamily) and 5 type II receptors (3 for the BMP subfamily) have
been described. In general, BMPs signal via one subset of SMAD
proteins (SMAD1, SMAD5, and SMAD8), while TGF-b ligands
signal via another subset (SMAD2 and SMAD3) [1–2]. Other
noncanonical signaling cascades can also be activated, but the
molecular mechanisms are less well understood [1–2]. One
important question in the field is how the BMP/TGF-b superfam-
ily is able to exert a cell-context specific effect through a limited
number of type I and type II receptors and intracellular SMAD
proteins.
Recently, we discovered a novel family of proteins, the repulsive
guidance molecule (RGM) family, that function as co-receptors for
the BMP signaling pathway [3–5]. This family is comprised of 3
members, RGMA, RGMB, and RGMC (also known as
hemojuvelin, hereafter referred to as HJV), that share 50–60%
amino acid identity and similar structural features, including an N-
terminal signal peptide, proteolytic cleavage site, partial von
Willebrand factor type D domain, and glycophosphatidylinositol
(GPI) anchor [6–11]. We have previously demonstrated that all
RGMs bind to BMP ligands and BMP type I and type II receptors
to enhance intracellular SMAD phosphorylation and BMP-
SMAD target gene transcription in response to BMP ligands [3–
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enables cells to selectively respond to low levels of BMP ligands [3–
5]. At least some members of the RGM family have also been
shown to be released from the cell in soluble form (lacking the GPI
anchor) [8–9,12–17], and soluble RGM proteins can act as
inhibitors of the BMP signaling pathway by sequestering BMP
ligands [3,18–19].
RGM family members are differentially expressed in a wide
range of tissues, and have been suggested to have diverse biologic
roles ranging from repulsive axonal guidance (giving rise to the
family name), neural tube closure, neuronal differentiation, cell
survival, axonal regeneration after injury, immunity, inflamma-
tion, and iron homeostasis regulation [2–11,20–33]. Some of these
biologic actions depend on the BMP signaling function of RGM
family members [5,7,18–21,32–33], while others appear to be
independent of the BMP signaling function of RGMs [23–24,26–
30].
HJV has the most well characterized biologic role among the
RGM family that depends on its function as a BMP co-receptor.
Mutations in the gene encoding HJV lead to the iron overload
disorder juvenile hemochromatosis in both human patients and
mice as a direct result of impaired BMP-SMAD signaling in the
liver and consequent deficiency of the main iron regulatory
hormone hepcidin [5,7,20–21]. The central role of the BMP-
SMAD pathway in hepcidin regulation and systemic iron balance
is further supported by the fact that mutations in the genes
encoding the ligand BMP6 [18,34], BMP type I receptors ALK2
and ALK3 [35], or common-mediator SMAD4 [36] all lead to
hepcidin deficiency and iron overload similar to HJV mutations.
Furthermore, pharmacologic modulators of the BMP-SMAD
signaling pathway regulate hepcidin expression and systemic iron
balance in normal mice [18–19,37], and ameliorate iron overload
due to hepcidin deficiency and anemia due to hepcidin excess in
animal models [38–39].
Interestingly, indirect evidence from binding competition and
biological inhibition assays using soluble RGM proteins lacking
the GPI anchor fused to the Fc tail of human IgG (RGM.Fc)
suggest that RGM proteins do not bind to all BMP ligands with
equal affinity [3–5,18–19,40]. Biologic assays in cell culture
systems also suggest that RGMs utilize some BMP ligands
preferentially [4–5,40–42]. The differential binding of RGMs to
BMP ligands may provide insight into their biologic functions, and
into the mechanisms by which BMPs generate a cell-context
specific effect. Here, we used surface plasmon resonance (SPR) to
quantitate the binding kinetics of RGM proteins to a wide array of
BMP ligands including BMP2, BMP4, BMP5, BMP6, BMP7 and
BMP9.
Materials and Methods
Surface Plasmon Resonance (SPR)
All SPR kinetics experiments were carried out on a Biacore
T200 (GE Healthcare) except for BMP9, which was performed on
an earlier model Biacore T100 (GE Healthcare). Recombinant
human BMP2, BMP4, BMP5, BMP6, BMP7, BMP9, RGMA,
RGMB, HJV (RGMC), and ALK1-Fc were obtained from R&D
Systems in carrier-free forms. BMPs, RGMs and ALK1-Fc were
reconstituted in sterile PBS as 1 mg/ml stock solutions, except for
BMP6, which was supplied in Acetonitrile and TFA solution from
R&D Systems at concentrations from 0.535 mg/ml to 0.788 mg/ml
as indicated by the manufacturer.
BMP2, BMP4, BMP5, BMP6 and BMP9 were diluted in
sodium acetate pH 4.5 (GE Healthcare) and immobilized by the
amine coupling method on a CM5 sensor chip according to the
manufacturer’s protocol (GE Healthcare). BMP7 was immobilized
on a CM4 sensor chip using the same protocol. Flow cells 2
through 4 were immobilized with a ligand, and flow cell 1 was
equally treated but without protein as a control. The immobili-
zation levels of ligands ranged from 50 to 300 RU, determined
empirically to optimize each kinetics interaction and reduce mass
transport limitation. Low immobilization levels were used to
minimize possible mass transport limitation, and at least 2 different
immobilization levels were used for each interaction tested. In all
cases, data obtained from different immobilization levels showed
no significant difference. Analytes (RGMA, RGMB, HJV and
ALK1-Fc) were diluted in running buffer HBS-EP+ (GE
Healthcare) at concentrations ranging from 2 nM to 1200 nM,
generally with a series of five 2-fold escalations to a maximum
concentration about 10-fold higher than the KD, with occasional
variations as needed to improve fitting. Analytes were injected
through all channels at a flow rate of 30 ml/min, a flow rate
chosen from a mass transport limitation test to minimize mass
transport limitation, and above which further increases had no
significant impact on binding curves. Middle concentrations were
run in duplicate at the end of each multicycle run to confirm the
stability of the surface during each run. The association and
dissociation times were typically 240 seconds and 480 seconds,
occasionally modified where indicated to optimize each interac-
tion. The sensor surface was regenerated after each injection cycle
to allow interaction between surface and fresh ligands for the next
cycle. The regeneration condition was optimized by regeneration
scouting as Glycine-HCl pH 2.2 (GE Healthcare) at a flow rate of
50 ml/min for 30 seconds followed by 30 seconds of stabilization.
The sensograms of flow cells 2, 3, and 4 were subtracted from
the flow cell 1 control. The kinetic fitting was carried out with
Biacore T200 evaluation software by global fitting using 1:1
Langmuir binding model (A + B=AB). The kinetics data were
calculated as Kon (association rate), Koff (dissociation rate) and KD
(KD=K off/Kon). Each SPR run was evaluated based on the
recommended range of several statistical measurements provided
by the Biacore T200 evaluation software including x
2 (measures
how closely a model fits the experimental data); U value (indicates
if the parameters are uniquely decided); tc (a measure of mass
transport limitation); and T-values (analogous to signal-to-noise for
the fitted parameter values). All experiments were repeated
between 4–9 times.
Luciferase Assay
Soluble RGMA and HJV (lacking the GPI anchor) fused to the
Fc portion of human IgG (RGMA.Fc and HJV.Fc) were generated
[4,19] and purified [19] as previously described. Hepatoma-
derived Hep3B cells were transfected with the hepcidin promoter
firefly luciferase construct [5] and a control Renilla luciferase
vector (pRLTK, Promega). Transfected cells were incubated
alone, with BMP ligands (5 ng/ml BMP9, 50 ng/ml BMP5, or
25 ng/ml BMP2, BMP4, BMP6, or BMP7), or with the BMP
ligands plus 0.2 to 50 mg/ml RGMA.Fc or HJV.Fc, followed by
measurement of relative luciferase activity by dual luciferase assay
(Promega) as previously described [19].
Statistics
Statistical significance was determined by one-way analysis of
variance (ANOVA) with the Bonferroni’s or Dunnett’s post-hoc
tests for pair-wise multiple comparisons as indicated. Statistical
analysis was conducted using Prism 4.0 (La Jolla, CA) statistical
software and P,0.05 was considered significant.
Binding Kinetics of RGMs for BMPs
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HJV Exhibits Preferential Binding to the BMP6/BMP5/
BMP7 Subfamily Compared with RGMA and RGMB, with
the Highest Affinity for BMP6
We have previously demonstrated that HJV binds to BMP6 and
that Bmp6 knockout mice exhibit an equivalent iron overload
phenotype to Hjv knockout mice suggesting that BMP6 is an
important endogenous ligand for HJV in the regulation of
hepcidin expression and systemic iron balance [18,34]. We
therefore quantitated the binding kinetics of HJV to BMP6 using
surface plasmon resonance (SPR). Results were compared with the
binding of other RGM family members (RGMA and RGMB) to
BMP6. Results were also compared to the closely related BMP5
and BMP7 ligands, which together with BMP6, share 71–80%
amino acid identity in the mature region and constitute a subfamily
of the BMP ligands [43]. Mean KD,K on, and Koff from 4–9
experiments for each interaction are reported in Figure 1 and
Figure 2, while representative sensograms are shown in Figure S1,
Figure S2, and Figure S3.
As shown in Figure 1, HJV bound to BMP6 with high affinity
(KD 8.1 nM). In comparison, RGMB and RGMA bound to
BMP6 with about 3.5- and 5-fold lower affinity (KD 28 nM and
55 nM respectively) (Figure 1). The higher affinity of HJV for
BMP6 was due to a combination of a faster association rate and
slower dissociation rate compared with the other RGM proteins
(Figure 2).
HJV bound to BMP5 with about 2-fold lower affinity (KD
17 nM) than BMP6 (Figure 1). This lower affinity was mostly due
to a slower association rate of HJV for BMP5 compared with
Figure 1. Binding affinity of RGM proteins for BMP ligands. (A)
The binding affinity (KD=K off/Kon) of each RGM protein for each BMP
ligand was measured by surface plasmon resonance and plotted as
mean 6 SD (n=4–9 per group). The mean KD 6 SD of RGM proteins for
BMP2 and BMP4 is also shown as an inset to better demonstrate their
lower KD values. The mean KD is reported numerically in (B). (A) Black
bar: HJV; gray bar: RGMB; white bar: RGMA. Statistical significance
among 3 RGM proteins for binding to each BMP ligand was determined
by one-way analysis of variance (ANOVA) with the Dunnett’s post-hoc
test for pair-wise multiple comparisons (* all comparisons are significant
(P,0.05)). For comparisons among 5 BMP ligands for binding to each
RGM protein, one-way ANOVA with the Bonferroni’s post-hoc test was
used (# all comparisons are significant (P,0.05); $ not all comparisons
are significant: for HJV, all pair-wise comparisons between BMP ligands
are significant except for BMP2 vs BMP6; for RGMB, all pair-wise
comparisons between BMP ligands are significant except for BMP2 vs
BMP4 and BMP5 vs BMP6; for RGMA, all pair-wise comparisons between
BMP ligands are significant except for BMP2 vs BMP4, BMP5 vs BMP7
and BMP6 vs BMP7.
doi:10.1371/journal.pone.0046307.g001
Figure 2. Association rate (Kon) and dissociation rate (Koff)
between RGM proteins and BMP ligands. The association rate (Kon,
A), and dissociation rate (Koff, B) between each RGM protein and each
BMP ligand was measured by SPR and plotted as mean 6 SD (n=4–
9 per group). Black bar: HJV; gray bar: RGMB; white bar: RGMA.
Statistical significance was determined as described in Figure 1. For
comparisons among 3 RGM proteins for each BMP ligand: * all
comparisons are significant (P,0.05); & not all comparisons are
significant, as detailed below; NS all comparisons are not significant
(P.0.05). For comparisons among 5 BMP ligands for each RGM protein:
# all comparisons are significant (P,0.05); $ not all comparisons are
significant, as detailed below. (A) $: For HJV, all pair-wise comparisons
between BMP ligands are significant except for BMP2 vs BMP6, BMP5 vs
BMP6, and BMP5 vs BMP7; for RGMB, all pair-wise comparisons between
BMP ligands are significant except for BMP5 vs BMP6; for RGMA, all pair-
wise comparisons between BMP ligands are significant except for BMP2
vs BMP5. &: For BMP7, all pairwise comparisons are significant except
for HJV vs RGMA (B) $: For HJV, all pair-wise comparisons between BMP
ligands are significant except for BMP2 vs BMP5, BMP4 vs BMP5, BMP4
vs BMP6, and BMP5 vs BMP6; for RGMB, all pair-wise comparisons
between BMP ligands are significant except for BMP2 vs BMP7 and
BMP5 vs BMP6; for RGMA, all pair-wise comparisons between BMP
ligands are significant except for BMP2 vs BMP4, BMP2 vs BMP7, BMP4
vs BMP7, and BMP6 vs BMP7. &: For BMP7, all pairwise comparisons are
significant except for RGMB vs R G M A ;f o rB M P 2 ,a l lp a i r w i s e
comparisons are significant except for RGMA vs RGMB; for BMP4, all
pairwise comparisons are significant except for RGMB vs HJV.
doi:10.1371/journal.pone.0046307.g002
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RGMA bound to BMP5 with about 2- and 5-fold lower affinity
(KD 33 nM and 83 nM respectively) compared with HJV
(Figure 1). RGMB binding to BMP5 was similar to BMP6, while
the lower affinity of RGMA for BMP5 compared with BMP6 was
mostly due to a faster dissociation rate (Figure 2).
All RGM proteins had lower or equivalent affinity for BMP7
compared with BMP6 or BMP5 (Figure 1). This was mainly due to
a slower association rate, although RGMs, particularly HJV, also
tended to have a slower dissociation rate for BMP7 (Figure 2).
These slower kinetics and the need for higher concentrations of
analyte yielded poor fitting of BMP7-RGM interactions on CM5
sensor chips, necessitating the use of CM4 sensor chips for these
interactions, which yielded reasonable fitting. As a control, we
obtained similar results for BMP6-HJV interaction on CM4 sensor
chips compared with CM5 sensor chips (data not shown). HJV
had the highest affinity for BMP7 among the RGMs (KD 20 nM)
followed by RGMA and RGMB (KD 63 nM and 166 nM
respectively) (Figure 1). This was mainly due to a very slow
dissociation rate of HJV for BMP7 (Figure 2).
RGMB Exhibits Preferential Binding to the BMP2/BMP4
Subfamily Compared with HJV and RGMA, with the
Highest Affinity for BMP4
Next, we tested the binding kinetics of RGM proteins for
another main subfamily of BMP ligands, BMP2 and BMP4, which
possess 86% amino acid identity to each other, but only 54–60%
identity to the BMP6/BMP5/BMP7 subfamily in the mature
region [43]. Mean KD,K on, and Koff from 4–9 experiments for
each interaction are reported in Figure 1 and Figure 2, while
representative sensograms are shown in Figure S4 and Figure S5.
As shown in Figure 1, RGMB had the highest binding affinity
for BMP2 among the RGMs (KD 5.5 nM). This was about 5-30-
fold higher than the affinity of RGMB for the BMP6/BMP5/
BMP7 subfamily (Figure 1), mostly due to a faster association rate
(Figure 2). HJV had intermediate binding affinity for BMP2
among the RGM family (KD 9.4 nM), about 1.6-fold lower than
RGMB and about 2.5-fold higher than RGMA (Figure 1). In
contrast to RGMB, the affinity of HJV for BMP2 was nearly
identical to the binding affinity of HJV for BMP6 (Figure 1).
Similar to most of the other BMPs tested, RGMA exhibited the
lowest binding affinity among the RGMs for BMP2 (KD 22 nM,
Figure 1), mostly due to a slower association rate compared with
the other RGMs (Figure 2). RGMA was similar to RGMB in that
it exhibited preferential binding to BMP2 compared with the
BMP6/BMP5/BMP7 subfamily, about 2-4-fold higher (Figure 1).
This was due to a combination of a slower dissociation rate and
faster association rate of RGMA for BMP2 compared with the
BMP6/BMP5/BMP7 subfamily (Figure 2).
The relative affinity of RGM family members for BMP4 was
very similar to BMP2 (Figure 1). RGMB had the highest binding
affinity for BMP4 (KD 2.6 nM), about 2-fold higher than HJV (KD
4.5 nM) and 5–6-fold higher than RGMA (KD 14 nM) (Figure 1).
Interestingly, BMP4 had the highest affinity for all RGM proteins
relative to the other BMPs tested (Figure 1), mostly due to a faster
association rate, and, to a lesser extent, a slower dissociation rate
(Figure 2). The affinity of all of the RGMs for BMP4 was about 2-
fold higher than BMP2 (although this difference was not
statistically significant for RGMA or RGMB). Similar to the
results for BMP2, RGMB exhibited a strong preferential binding
to BMP4 compared with the BMP6/BMP5/BMP7 subfamily,
about 10- to 64-fold (Figure 1), mostly due to a faster association
rate (Figure 2). RGMA exhibited an intermediate preferential
binding for BMP4 compared with the BMP6/BMP5/BMP7
subfamily, about 4- to 6-fold (Figure 1), due to a combination of
a faster association rate and slower dissociation rate (Figure 2).
HJV bound to BMP4 with only about 2-4-fold higher affinity than
the BMP6/BMP5/BMP7 subfamily (Figure 1), mostly due to
a faster association rate (Figure 2).
RGM Family Members do not Bind BMP9
BMP9 exhibits 50–55% amino acid identity to BMP2, BMP4,
BMP5, BMP6, and BMP7 [44], and has also been demonstrated
to stimulate hepcidin expression in liver-derived cells in culture
[19]. We therefore tested the binding kinetics of HJV and other
RGM family members for BMP9 using SPR. In contrast to the
other BMP ligands tested, BMP9 did not bind to any of the RGM
family members (Figure S6A–C). As a positive control, BMP9 was
able to bind to the soluble portion of the BMP type I receptor
ALK1 fused to the Fc region of human IgG (ALK1-Fc, Figure
S6D), as previously demonstrated [45].
Soluble RGM Proteins Fused to the Fc Portion of Human
IgG (RGM.Fc) Selectively Inhibit the Biologic Activity of
BMP Ligands
To provide independent confirmation of the relative binding
affinities of RGM family members for BMP ligands measured by
SPR, we tested the ability of soluble RGMA.Fc fusion proteins to
inhibit the biologic activity of BMP ligands in a cell culture system.
Analogous data have previously been published for HJV.Fc and
RGMB.Fc [18–19]. The mechanism by which these RGM.Fc
fusion proteins inhibit BMP biologic activity is by binding and
sequestering BMPs to prevent them from interacting with cell
surface BMP receptors [19]. The biologic activity of BMP ligands
we studied was the ability to induce hepcidin promoter activity in
hepatoma-derived Hep3B cells as measured by dual luciferase
assay, which we have previously well characterized [19].
RGMA.Fc inhibited the biologic activity of BMP4 and BMP2
most robustly, with lesser inhibition of BMP5, BMP6, and BMP7,
and no inhibition of BMP9 (Figure 3A). In a head-to-head
comparison, HJV.Fc was more potent than RGMA.Fc at
inhibiting the biologic activity of BMP6 (Figure 3B). These
functional data in a cell culture system support the relative binding
constants measured by SPR (Figure 1).
Discussion
Here, we used SPR to perform the first comprehensive
quantitative comparison of the binding interactions between the
RGM family of BMP co-receptors and BMP ligands. We
demonstrated that RGM proteins exhibited a wide range of
binding affinities for BMP2, BMP4, BMP5, BMP6, and BMP7
ligands ranging from 2.6 nM to 166 nM, and none of the RGMs
bound to BMP9. One characteristic feature shared by all of the
RGM proteins is the order of preferential binding to the various
BMP ligands. All RGMs exhibited the highest binding affinity for
BMP4, followed in order by BMP2, BMP6, BMP5, and BMP7,
while none of the RGMs bound to BMP9. However, one notable
difference between the RGM proteins is that the binding affinity of
HJV for the BMP6/BMP5/BMP7 subfamily was significantly
higher than RGMB and RGMA, and was very close to the binding
affinity of HJV for BMP4 and BMP2. In contrast, RGMB and to
a lesser extent RGMA exhibited a much weaker binding to the
BMP6/BMP5/BMP7 subfamily compared with the BMP4/BMP2
subfamily, and compared with HJV.
Binding affinities have previously been reported for the
interaction between BMP2 and all RGM family members, and
BMP4 binding to RGMA in 4 prior studies [3,40,46–47]. An
Binding Kinetics of RGMs for BMPs
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fusion proteins, which form dimers [3,40,46], whereas we used
monomeric proteins since HJV is predicted to be monomeric [47].
Therefore, results in these prior studies may be confounded by
avidity effects. One prior study measured the binding affinity of
monomeric HJV to BMP2 by SPR [47] and reported a 15-fold
lower affinity (KD 140 nM) compared to our study. However,
Yang et al. used an equilibrium based binding assay [47] rather
than binding kinetics as in our study, and real equilibrium may not
have been achieved in their study.
The relative binding constants measured by SPR in this study
are largely consistent with prior studies of the binding of RGM
proteins to BMP ligands, and the biologic activity of RGMs and
RGM.Fc fusion proteins in cell culture systems [3–5,18–19,40–
42]. Cell-free iodinated protein interaction and pull-down assays
have previously demonstrated that all RGMs bind to BMP2 and
BMP4, and that HJV binds to BMP6 [3–5,18]. For all RGMs,
excess cold BMP7 was unable to compete for binding to BMP2
and BMP4, suggesting preferential binding of RGMs to BMP2
and BMP4 versus BMP7 [3–5], consistent with the results in this
study.
Prior studies have also demonstrated that transfection of cDNAs
encoding each RGM increased BMP2 and BMP4 signaling, but
not BMP7 signaling, in cell culture systems [3–5,40–42].
Additionally, transfection of cDNAs encoding HJV, but not
RGMA or RGMB, mediated BMP6 signaling in cell culture
systems that expressed high levels of endogenous BMP6 [40–42].
Thus, all RGMs can mediate BMP2 and BMP4 signaling and
HJV can mediate BMP6 signaling in cell culture systems,
consistent with the highest binding affinities measured for these
interactions by SPR in this study.
Biologic inhibition assays in hepatoma-derived cell cultures
using soluble RGM.Fc fusion proteins to inhibit BMP ligand-
mediated hepcidin promoter luciferase activity have previously
demonstrated that HJV.Fc inhibited BMP4, BMP2, BMP6 and
BMP5 most robustly with lesser inhibition of BMP7 and no
inhibition of BMP9 [19], while RGMB.Fc inhibited BMP4 and
BMP2 most robustly, with lesser inhibition of BMP6, BMP5, and
BMP7 and no inhibition of BMP9 [18]. In a head-to-head
comparison, HJV.Fc inhibited BMP6 more robustly than
RGMB.Fc [18]. Together with the biological inhibition data
using RGMA.Fc here (Figure 3), these data overall support the
relative binding affinities measured by SPR in this study (Figure 1).
These data also provide further insight into a potential therapeutic
role for exogenously administered RGM.Fc proteins as selective
BMP signaling pathway inhibitors. For example, HJV.Fc has been
previously demonstrated to inhibit BMP-mediated hepcidin
expression and improve iron availability in vivo [18–19,39]. These
data may also shed light on a functional role for endogenous forms
of soluble RGM proteins as selective BMP pathway inhibitors,
particularly HJV, which has been found in measurable levels in
circulation [12,48–50].
Interestingly, all RGMs were demonstrated to bind to BMP7 by
SPR in the current study, whereas BMP7 was unable to compete
with BMP2 and BMP4 for RGM binding in iodinated protein
interaction studies [3–5], RGMs were not demonstrated to
increase BMP7 signaling in cell culture systems [40–42], and
RGM.Fc proteins demonstrated only a limited ability to inhibit the
biological activity of BMP7 in hepcidin promoter luciferase cell
culture assays (Figure 3) [18–19]. This was particularly notable for
HJV, where the overall affinity of the HJV-BMP7 interaction was
only about 2.5-fold lower than that for the HJV-BMP6 interaction
by SPR, while HJV.Fc was much less potent at inhibiting BMP7
compared with BMP6 activity in the hepcidin promoter luciferase
assays [19]. One explanation for these differences is the slow
kinetics of the RGM-BMP7 interactions. The reason for the
relatively higher overall affinity for the HJV-BMP7 interaction
measured by SPR was the very slow dissociation rate. However, all
RGM-BMP7 interactions had a very slow association rate, and
this slow association rate may have been the limiting factor
precluding any apparent biologic activity of RGM-BMP7 inter-
actions in the binding competition and cell culture assays. Second,
there may have been avidity effects from the use of dimeric
RGM.Fc fusion proteins in the biologic inhibition assays, while
RGM monomers were used in SPR. Additionally, the binding
characteristics of RGMs to BMP ligands in solution in the biologic
assays may be different compared with BMP ligands that are
covalently bound to sensor chips in SPR. Finally, the inability of
BMP7 to compete for BMP2 and BMP4 binding could also be
explained by nonoverlapping binding sites for BMP7 and BMP2/
BMP4 on RGMs. Future studies will be needed to delineate the
precise BMP binding domain(s) on RGMs, and whether the ability
Figure 3. Soluble RGMA.Fc selectively inhibits BMP induction
of hepcidin promoter luciferase activity. (A) Hep3B cells were
transfected with the hepcidin promoter firefly luciferase construct and
the control Renilla pRL-TK vector. Transfected cells were incubated
alone, with 5 ng/ml BMP9, 50 ng/ml BMP5, or 25 ng/ml BMP2, BMP4,
BMP6, or BMP7 ligands, or with the BMP ligands plus 0.2 to 50 mg/ml
RGMA.Fc as indicated, followed by measurement of relative luciferase
activity. (B) Hep3B cells were transfected as indicated in Panel A.
Transfected cells were incubated alone, with 25 ng/ml BMP6 ligand, or
with 25 ng/mL BMP6 ligand plus 0.2 to 50 mg/ml RGMA.Fc or HJV.Fc as
indicated followed by measurement of relative luciferase activity. (A–B)
Results are reported as the mean 6 SD of the percent decrease in
relative luciferase activity for cells treated with BMP ligands in
combination with RGMA.Fc or HJV.Fc compared with cells treated with
BMP ligands alone (n=3–4 per group).
doi:10.1371/journal.pone.0046307.g003
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biologic activity.
Among the RGMs, HJV had the highest binding affinity for
BMP6 at 8.1 nM. This is consistent with data from a biologic
inhibition assay showing that soluble HJV.Fc fusion protein
inhibited BMP6 induction of hepcidin promoter luciferase activity
more strongly than RGMB.Fc [19] and RGMA.Fc (Figure 3). This
is also consistent with the known physiologic role of HJV and
BMP6 in vivo in regulating liver hepcidin expression and systemic
iron balance [5,7,18–21,34]. Indeed, it is not surprising that HJV
expression is critical for BMP6-mediated induction of hepcidin in
response to iron given the relatively low affinity (KD 1.6 to 39 mM)
of BMP6 for the BMP type I and type II receptors that have been
demonstrated to be involved in this process [41,51]. We
hypothesize that expression of HJV in hepatocytes enables these
cells to respond specifically to low levels of BMP6 that are
produced in the liver in response to iron to stimulate hepcidin
expression. The significantly lower affinity of RGMB and RGMA
for BMP6 may help explain why these proteins cannot compensate
for the loss of HJV in regulating hepcidin expression and systemic
iron balance. Of note, HJV bound to BMP2 and BMP4 with equal
or 2-fold higher affinity than BMP6. Additionally, HJV also
exhibited preferential binding to BMP5 and BMP7 compared with
RGMB and RGMA. These data raise the possibility that HJV
could also have a role in regulating signaling by binding to one or
more of these other BMP ligands. Interestingly, BMP2 was
recently postulated to have a role in upregulating hepcidin
expression in multiple myeloma [52].
RGMB knockout mice exhibit early postnatal death, confirming
an important biologic function for RGMB, but the cause of this
premature death is still poorly understood [32]. RGMB has also
been implicated in axonal regeneration after injury [33], the
regulation of inflammatory cytokine expression in immune cells
[32], and renal tubule tight junction formation and transepithelial
resistance [42], all of which appear to be mediated by RGMB’s
BMP signaling function [32–33,42]. Notably, BMP4 and BMP2
ligands have been implicated in these processes [32–33,42],
consistent with the preferential affinity of RGMB for BMP4 and
BMP2 compared with HJV and RGMA and the other BMP
ligands.
RGMA has been demonstrated to mediate repulsive axonal
guidance (giving rise to the family name), neural tube closure,
neuronal differentiation, cell survival, inflammation and immune
cell function [2,6,9,22–31]. Many of these actions depend on an
interaction with neogenin, a homologue of the netrin receptor
deleted in colon cancer [23–24,26–30], while the BMP signaling
function of RGMA has not been clearly linked to its observed
biologic actions. Notably, RGMA exhibited the lowest affinity for
most of the BMP ligands tested relative to other RGM family
members, with the exception of slightly higher affinity for BMP7
compared with RGMB (which were the 2 lowest affinity
interaction measured). Thus, RGMA may have a less prominent
role as a BMP co-receptor compared with the other RGM
proteins. Nevertheless, RGMA still exhibits a binding affinity as
low as 14 nM to 23 nM to the BMP4/BMP2 subfamily, which
leaves open a possible physiologic role for the BMP signaling
function of RGMA.
In summary, the members of the RGM family of BMP co-
receptors exhibit preferential binding for different subsets of BMP
ligands. Relative to other RGMs, HJV has the highest affinity for
binding to BMP6, consistent with the important physiologic role of
HJV-mediated BMP6 signaling in regulating iron homeostasis.
These data provide important insights into mechanisms by which
BMP signals are finely tuned to exert cell-specific effects.
Supporting Information
Figure S1 Representative sensograms of kinetics ex-
periments between BMP6 and RGM proteins by SPR. (A)
HJV protein was diluted in running buffer HBS-EP+ into a series
of concentration (6.25, 12.5, 25, 50 and 100 nM) and injected
through CM5 chip immobilized with BMP6 at a density of
87.5 RU. (B) RGMB protein was diluted in running buffer HBS-
EP+ into a series of concentration (18.75, 37.5, 75, 150 and
300 nM) and injected through CM5 chip immobilized with BMP6
at a density of 287.3 RU. (C) RGMA protein was diluted in
running buffer HBS-EP+ into a series of concentration (30, 75,
150, 300 and 600 nM) and injected through CM5 chip
immobilized with BMP6 at a density of 150 RU. (A–C) Color
lines represent the fitted curves plotted from the 1:1 Langmuir
binding model and the black line represents the experimental
curves. The kinetics data (KD,K on, and Koff) and quality control
parameters (x
2, U, T(Kon) and T(Koff)) are shown in the tables
below each sensogram.
(TIF)
Figure S2 Representative sensograms of kinetics ex-
periments between BMP5 and RGM proteins by SPR. (A)
HJV protein was diluted in running buffer HBS-EP+ into a series
of concentration (10, 20, 40, 80 and 160 nM) and injected through
CM5 chip immobilized with BMP5 at a density of 287.4 RU. (B)
RGMB protein was diluted in running buffer HBS-EP+ into
a series of concentration (12.5, 25, 50, 100 and 200 nM) and
injected through CM5 chip immobilized with BMP5 at a density
of 527.5 RU. (C) RGMA protein was diluted in running buffer
HBS-EP+ into a series of concentration (50, 100, 200, 400 and
800 nM) and injected through CM5 chip immobilized with BMP5
at a density of 436.1 RU. (A–C) Color lines represent the fitted
curves plotted from the 1:1 Langmuir binding model and the black
line represents the experimental curves. The kinetics data (KD,
Kon, and Koff) and quality control parameters (x
2, U, T(Kon) and
T(Koff)) are shown in the tables below each sensogram.
(TIF)
Figure S3 Representative sensograms of kinetics ex-
periments between BMP7 and RGM proteins by SPR. (A)
HJV protein was diluted in running buffer HBS-EP+ into a series
of concentration (50, 100, 200, 400 and 800 nM) and injected
through CM4 chip immobilized with BMP7 at a density of
284.9 RU. (B) RGMB protein was diluted in running buffer HBS-
EP+ into a series of concentration (18.75, 37.5, 75, 150 and
300 nM) and injected through CM4 chip immobilized with BMP7
at a density of 365.6 RU. (C) RGMA protein was diluted in
running buffer HBS-EP+ into a series of concentration (75, 150,
300, 600 and 1200 nM) and injected through CM4 chip
immobilized with BMP7 at a density of 286.9 RU. (A–C) Color
lines represent the fitted curves plotted from the 1:1 Langmuir
binding model and the black line represents the experimental
curves. The kinetics data (KD,K on, and Koff) and quality control
parameters (x
2, U, T(Kon) and T(Koff)) are shown in the tables
below each sensogram.
(TIF)
Figure S4 Representative sensograms of kinetics ex-
periments between BMP2 and RGM proteins by SPR. (A)
HJV protein was diluted in running buffer HBS-EP+ into a series
of concentration (6.25, 12.5, 25, 50 and 100 nM) and injected
through CM5 chip immobilized with BMP2 at a density of
118 RU. (B) RGMB protein was diluted in running buffer HBS-
EP+ into a series of concentration (2, 4, 8, 15 and 30 nM) and
injected through CM5 chip immobilized with BMP2 at a density
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HBS-EP+ into a series of concentration (10, 20, 40, 80 and
160 nM) and injected through CM5 chip immobilized with BMP2
at a density of 198.5 RU. (A–C) Color lines represent the fitted
curves plotted from the 1:1 Langmuir binding model and the black
line represents the experimental curves. The kinetics data (KD,
Kon, and Koff) and quality control parameters (x
2, U, T(Kon) and
T(Koff)) are shown in the tables below each sensogram.
(TIF)
Figure S5 Representative sensograms of kinetics ex-
periments between BMP4 and RGM proteins by SPR. (A)
HJV protein was diluted in running buffer HBS-EP+ into a series
of concentration (5, 10, 20, 40 and 80 nM) and injected through
CM5 chip immobilized with BMP4 at a density of 40.2 RU. (B)
RGMB protein was diluted in running buffer HBS-EP+ into
a series of concentration (2, 4, 8, 16 and 32 nM) and injected
through CM5 chip immobilized with BMP4 at a density of
96.1 RU. (C) RGMA protein was diluted in running buffer HBS-
EP+ into a series of concentration (10, 20, 40, 80 and 160 nM) and
injected through CM5 chip immobilized with BMP4 at a density
of 95.2 RU. (A–C) Color lines represent the fitted curves plotted
from the 1:1 Langmuir binding model and the black line
represents the experimental curves. The kinetics data (KD,K on,
and Koff) and quality control parameters (x
2, U, T(Kon) and
T(Koff)) are shown in the tables below each sensogram.
(TIF)
Figure S6 Representative sensograms of kinetics ex-
periments between BMP9 and RGM proteins, and BMP9
binding to ALK1-Fc by SPR. (A) HJV protein was diluted in
running buffer HBS-EP+ into a series of concentration (10, 25, 50,
100 and 200 nM) and injected through CM5 chip immobilized
with BMP9 at a density of 139.1 RU. (B) RGMB protein was
diluted in running buffer HBS-EP+ into a series of concentration
(2, 4, 8, 15 and 30 nM) and injected through CM5 chip
immobilized with BMP9 at a density of 160.7 RU. (C) RGMA
protein was diluted in running buffer HBS-EP+ into a series of
concentration (6, 12, 25, 50 and 100 nM) and injected through
CM5 chip immobilized with BMP9 at a density of 160.7 RU. (A–
C) No significant binding was detected and kinetics data cannot be
calculated. (D) ALK1-Fc protein was diluted in running buffer
HBS-EP+ into 100 nM and injected through CM5 chip
immobilized with BMP9 at a density of 160.7 RU.
(TIF)
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